Efficacy and Safety of Cholinesterase Inhibitors and Memantine in Cognitive Impairment in Parkinsons Disease, Parkinsons Disease Dementia, and Dementia with Lewy Bodies: Systematic Review with Meta-Analysis and Trial Sequential Analysis
JNNP 86:135-143, Wang, H.F.,et al, 2015
Practice Parameter: Evaluation and Treatment of Depression, Psychosis, and Dementia in Parkinson Disease (An Evidence-Based Review)
Neurol 66:996-1002, Miyasaki,J.M.,et al, 2006
Non-Alzheimers Dementia 2 Lewy Body Dementias
Lancet 386:1683-1697, Walker, Z.,et al, 2015
Patterns and Trends in Antipsychotic Prescribing for Parkinson Disease Psychosis
Arch Neurol 68:899-904, Weintraub, D.,et al, 2011
Dementia and Survival in Parkinson Disease: A 12-Year Population Study
Neurol 70:1017-1022, Buter,T.C.,et al, 2008
Quetiapine for Agitation or Psychosis in Patients with Dementia and Parkinsonism
Neurol 68:1356-1363, Kurlan,R.,et al, 2007
Donepezil for Dementia in Parkinsons Disease: A Randomised, Double Blind, Placebo Controlled, Crossover Study
JNNP 76:934-939,903, Ravina,B.,et al, 2005
Rivastigmine for Dementia Associated with Parkinson's Disease
NEJM 351:2509-2518,2547, Emre,M.,et al, 2004
The Nonmotor Problems of Parkinson's Disease
The Neurologist 6:18-27, Friedman,J.H.&Fernandez,H.H., 2000
Diagnostic Criteria for Parkinson Disease
Arch Neurol 56:33-39, Gelb,D.J.,et al, 1999
A Clinicopathologic Study of 100 Cases of Parkinson's Disease
Arch Neurol 50:140-148, Hughes,A.J.,et al, 1993